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ABSTRACT
Hypoxia-sensitive gene expression in the gastrocnemius muscle following chronic hind
limb ischemia
Andrew Tilton
Chronic ischemia, caused by the formation atherosclerotic plaque occlusions in
major conduit arteries, is the leading cause of morbidity and mortality in western
societies. Vascular remodeling can help compensate for the adverse effects of
atherosclerotic plaque formation. Vascular remodeling relies heavily on vascular
endothelial growth factor (VEGF), a critical protein that contributes to all forms of
vascular formation and remodeling including angiogenesis1, arteriogenesis2 and
vasculogenesis3. VEGF itself is up-regulated by the transcription factor, hypoxia
inducible factor 1 alpha (HIF-1α), which becomes activated in low oxygen environments.
Through the use of animal chronic hindlimb ischemia models, these genes can be
evaluated as potential therapeutic targets for chronic ischemia. A modified hindlimb
ischemia surgery that we evaluated significantly increases VEGF expression, but does not
cause an up-regulation of HIF-1α. This research lays the foundation for further
investigation into the animal chronic hindlimb ischemia model by providing the
necessary protocols and molecular biology techniques. The next step in this line of
research should focus on protein quantification in the gastrocnemius muscle and
verification of the gene expression profile described in this report.

1

: the growth of new blood vessels from pre-existing vessels
: the increase in diameter of pre-existing vessels in order to accommodate for greater
flow through them
3
: the growth of new blood vessels via de novo generation of endothelial cells
2
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Chapter 1. Introduction
OVERVIEW
Peripheral artery disease (PAD) is a condition of the vascular system in which
large arteries become occluded and prevent proper blood flow to the extremities [1]. The
disease is commonly caused by atherosclerotic plaque formation along the vascular walls,
which results in downstream ischemia [1]. Ischemia is characterized by insufficient blood
flow to tissues and leads to poor nutrient supply and hypoxia [2]. In healthy tissue,
vasodilation is used in response to the onset of hypoxia as a way to restore proper oxygen
levels in the tissue. In patients with PAD, vasoactivity is impaired and vessels cannot
vasodilate properly in response to signals from the tissue.
The disease is becoming more and more common as the rate of obesity continues
to increase in the U.S. There are several contributing factors that lead to the formation of
the plaque along the artery wall (Figure 1), including diabetes mellitus, smoking,
hypertension, and hypercholesteremia. The development of PAD in patients is an
accurate indicator of overall decreased cardiovascular health and suggests that blood
vessel occlusions are likely to develop elsewhere in the body as well. The general
symptoms are typically noticed in the legs, but blood flow will likely be reduced in the
heart and brain as well. Therefore, PAD is a useful indicator of many other related
conditions, including coronary heart disease, which can cause a myocardial infarction.
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Figure 1. Diagram of atherosclerotic plaque occluded artery of
PAD patient compared to normal artery. The figure depicts the
narrow lumen, characteristic of occluded artery [3].
PAD presents itself differently in every patient and about 20% of people with the
disease are asymptomatic [1]. The most common symptom of the disease is intermittent
claudication (irregular pain) in the extremities, caused by ischemia, and usually occurs
during locomotion. When PAD progresses to the point where the patient experiences
intermittent claudication, they have a significantly increased risk of mortality from
cardiovascular disease. In extreme cases of PAD, limb ischemia is so severe that
gangrene develops as a result of insufficient blood flow. It is not uncommon for these
symptoms to eventually result in amputation. Unfortunately, PAD is at times difficult to
detect, especially in asymptomatic patients.
Currently, the most commonly used diagnostic tool for assessing the status of a
patient with PAD is a simple and noninvasive procedure, called the Ankle Brachial
Pressure Index (ABPI) test [4]. The test is administered by using a Doppler ultrasound
2

instrument to detect blood flow to the lower extremities and a blood pressure cuff at the
arm. Using these devices together the blood pressure in the posterior tibial artery is
compared to the blood pressure in the brachial artery. The results from the test are
reported as a ratio between the lower leg and upper arm. Atherosclerotic plaques in
peripheral arteries will cause decreased blood flow in the lower extremities. A healthy
ABPI is in the range of 0.9-1.3 indicating that the blood pressure between the legs and
arms is roughly the same. ABPI ratios between 0.4 and 0.9 are indicative of moderate
PAD and values below 0.4 suggest severe PAD.
The atherosclerotic plaques responsible for the occlusions of PAD patients are
composed of three distinct layers [5]. The initial layer, found at the center of the plaque is
comprised of monocytes and other cellular debris. The plaques first begin to form where
turbulent flow occurs in the blood vessel, which generally occurs near a bifurcation. The
turbulent flow patterns induce the activation of endothelial cells, which line the blood
vessels, causing them to present adhesion molecules on their surface [6]. Among the
adhesion molecules presented is the protein, vascular cell adhesion protein 1 (VCAM-1),
which is recognized and bound by monocytes. Upon activation, monocytes begin to
differentiate into macrophages, which phagocytose oxidized low density lipoproteins
(LDL). This is an important step in the body’s natural defense against atherosclerotic
plaque formation because the lipoproteins build upon the first layer and enlarge the
occlusion [7]. However, the situation is exaggerated as the macrophages then presents
oxidized LDLs antigens on their surface and activate T helper cells [8]. As T helper cells
become activated they excrete inflammatory cytokines such as interferon-γ. The second
layer of the atherosclerotic plaque is primarily a crystalized coating of cholesterol and
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low-density lipoproteins that have accumulated at the site [8]. The final layer is a
calcification layer and is only present in older, more advanced, plaque. The calcification
makes the artery stiff and inflexible.

CURRENT TREATMENTS FOR PAD
The most important and effective treatment for patients with PAD is to monitor
the contributing causes of the disease and eliminate them whenever possible. For
example, maintaining a healthy diet and regular exercise routine will help lower blood
pressure and cholesterol. It is also important to monitor blood sugars and keep them
within a normal range. Current non-invasive treatments for PAD include cholesterollowering medications, hypertension medications, and anti-clotting agents to name a few
[1, 9].
Non-invasive treatments are much more desirable methods of curing patients
compared to invasive surgical methods because they are far less risky [1, 9]. With
cholesterol lowering medications, the goal is to reduce the patient’s risk of heart attack
and stroke. This method effectively targets and treats the underlying cause of PAD. It is
important in people with PAD to reduce their LDL levels to a healthy range (<100
mg/dL), in order to control fat and cholesterol transport throughout the body. When too
much LDL circulates in the blood, it can slowly build up along the inner walls of arteries
and aid in the formation of plaque.
Anti-coagulates are also widely prescribed to PAD patients as a way to help
reduce the risk of blood clots forming [1, 9]. Patients with PAD are at greater risk of clots
forming at the occlusion site because there is a reduced blood flow through the area. A
blood clot that forms in the artery can completely block the already narrowed blood
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vessel. This could lead to tissue death if not treated promptly. Further, if a clot that forms
in the leg manages to break away it can cause a stroke if it makes its way to the brain, or
cause a heart attack if it travels through a vital cardiac artery. However, while this
treatment is somewhat effective, it only addresses a symptom of the disease and does
nothing to treat the underlying cause.
However, while these drugs are somewhat effective, many of them merely treat
the symptoms rather than the cause of the disease. Another option that is highly effective
and minimally invasive is an angioplasty [1, 9]. An angioplasty (figure 2) is often used
when the PAD is causing intermittent claudication, or muscle pain, in the patient. An
angioplasty involves threading a catheter through the blood vessel to the affected region
of the artery. A balloon is located at the tip of the catheter, which can be inflated to
reopen the artery. At the same time, the occlusion is flattened into the artery wall and the
artery wall stretches, which increases blood flow. An optional addition to the procedure is
the use of a stent, or mesh frame that can be inserted into the site to help keep the artery
open even after the procedure is over.
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Figure 2. Diagram of angioplasty procedure depicting the process of
threading the catheter balloon into the occluded area where it can be
inflated to flatted the plaque and stretch the vessel wall thus increasing
blood flow through the vessel. Not shown is the process of stent insertion
[10].
Another surgical treatment implemented by doctors to treat PAD is bypass
surgery [1, 9]. While this procedure is equally effective, or even better for some patients,
it is far more complicated than the angioplasty procedure. This operation requires the
surgeon to create a graft bypass by using a vessel from somewhere else in the patient’s
body. However, recent advances are allowing for the use of synthetic vessels to be used.
The bypass procedure allows for blood to flow around the occluded region. One
limitation to these procedures is that they are only effective if only one artery is
obstructed. For more systemic conditions, these techniques will be largely ineffective. As
with any invasive surgery, there are risks, including infection or death.
While these treatments are somewhat effective and have helped many patients
suffering from PAD, they are insufficient for many people. The bypass procedure is
insufficient because without addressing the cause, another occlusion may quickly form
6

and vessels for additional bypass procedures may not be available. Angioplasty does not
always work either because the occluded vessels are too small, or have become calcified,
making them inaccessible by the catheter. For many patients, surgery is contraindicated
due to current health status and the risk of complications during the procedure. Therefore,
research to provide additional approaches is needed.

VASCULAR REMODELING AND REACTIVITY
When healthy, and functioning properly, tissues control blood flow via
autoregulation [11, 12]. This is the ability to adjust blood flow in response to various
signals such as vessel pressure and metabolic levels. Regular changes in blood vessel
diameter to regulate blood flow throughout the body are referred to as vasoactivity.
Vasoactivity is achieved through vasoconstriction and vasodilation (figure 3b) of the
vascular smooth muscle and serves two major physiological purposes [11, 12]. First, it
regulates systemic blood pressure and second, it is used to redirect blood flow through
different regions of the body. The ability of a vessel to constrict and dilate is imperative
to maintaining homeostasis in the tissue by meeting the demand of oxygen and nutrients
in the downstream tissues. In healthy tissue, vasodilation is used in response to the onset
of hypoxia to restore proper in response to the onset of hypoxia to restore proper oxygen
levels in the tissue. This effect can last for several hours. In patients with PAD, the
vasoactivity is impaired and vessels cannot vasodilate in response to signals from the
tissue.
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A.

B.

Figure 3 A) Blood vessel anatomy depicting the several layers that comprise the vessel and
enabling it to function [13]. B) Effects of vasodilation and constriction of blood vessel
diameter [14].
The vasculature can adapt to an arterial occlusion such as that caused by an
atherosclerotic plaque by network remodeling, which is primarily done in three distinct
ways. The first is vasculogenesis [15], which is the de novo generation of capillaries
through the merging of endothelial cells. Vasculogenesis primarily occurs during
embryonic development; however it also occurs in response to severe hypoxia. The
second form of remodeling is angiogenesis [16], where new capillaries grow from preexisting capillaries in response to tissue hypoxia. The third, and final, process used to
remodel the vascular network is arteriogenesis [16, 17], in which pre-existing vessels
increase in diameter to restore endothelial shear stresses following an increase in blood
flow through collateral flow paths. These three mechanisms can effectively compensate
for the effects of an atherosclerotic plaque, and are therefore targets for novel therapeutic
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modalities. When these mechanisms are implemented together, collaterals enlarge from
pre-existing vessels and are capable of delivering sufficient blood flow to the tissue. In
both vasculogenesis and angiogenesis, increasing the number of capillaries present allows
for improved diffusion in the ischemic region.
Molecular analysis of gene expression will be useful in better understanding
signaling pathways involved in the vascular remodeling response to arterial occlusion.
Angiogenesis can be induced by several factors, including hypoxia, which will be the
main focus of this paper [16, 18]. When a cell senses hypoxia, it activates the
transcription factor Hypoxia inducible factor 1 (HIF1) [18]. HIF1 is responsible for
increasing the transcription of hypoxia-sensitive genes encoding essential proteins
involved in the remodeling process, including several growth factors. One of the most
well studied genes up regulated by HIF1 is Vascular endothelial growth factor (VEGF)
[19]. VEGF stimulates both vasculogenesis and angiogenesis in response to tissue
hypoxia by inducing the division of endothelial cells (figure 4). It is typically highly
functional during embryonic development, following an injury, and following intense
muscle activity in an attempt to create new blood vessels. Once functional, it is capable
of binding the VEGF receptor expressed on endothelial cells. The receptor is a tyrosine
kinase (RTK), which begins an angiogenesis pathway. VEGF is essential for collaterals
and collateral growth, allowing a tissue to have several different pathways for blood to be
delivered. However, while VEGF is necessary for collateral proliferation, it alone is not
sufficient to overcome the hypoxia [20].
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Figure 4. VEGF pathway within endothelial cell showing the downstream
effects, which eventually result in proliferation and vascular permeability
[21].
HIF1 alpha (HIF1α) is a well-established transcription factor regulated by the
availability of oxygen to the cell [18, 19]. The protein is a heterodimer that is capable of
entering the nucleus of the cell, where it binds to specific regions of the DNA and
activates a variety of hypoxia response genes. HIF1α is, itself, regulated by the
transcription factor NF-κB. Post translation, HIF1α is maintained at appropriate levels via
Ard1 [22]. HIF1 is a constitutively active gene, in which transcripts are constantly being
produced and translated. However, under normoxic conditions, Ard1 acetylates a lysine
10

residue within the oxygen-dependent degradation domain, thus marking it for degradation
by ubiquitin. HIF1α is also involved in a positive feedback loop in which the functional
transcription factor binds to a promoter region and activates itself. Under low levels of
hypoxia, HIF1α can be active and functional without increasing its own transcription
level [23].
While vascular remodeling may help the body adapt to vascular occlusions by
creating a natural bypass, previous research in the MATR lab shows that it may also be a
detriment by impairing vascular reactivity [24]. Homeostasis heavily relies on
vasoactivity in order to sufficiently meet the oxygen and nutrient demand in tissues. The
process of vessel outward remodeling may impair vasodilation, most likely by
interrupting the vasodilation signal transmission of endothelial cells.
There are two likely explanations for the impaired vasodilation observed after
outward network remodeling takes place. The first possible explanation is that the
process of synthesizing new extracellular matrix material impairs the ability of smooth
muscle cells to contract and relax, and disables the vessels ability to undergo
vasoactivity. Another possible explanation is that inflammation, which occurs during
arteriogenesis and is a common symptom of PAD, causes endothelial dysfunction and
significantly diminishes blood flow. Normally, endothelial cells initiate vasodilation by
releasing nitric oxide caused by shear stress to the vessel. However, during inflammation,
superoxide is produced from cytokine activation of NADPH oxidase, which inactivates
nitric oxide thus inhibiting the endothelial cells ability to induce vasodilation [25].
These explanations for impaired vasodilation observed in mouse models may also
explain the impaired vasoactivity seen in patients with PAD where inflammatory
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responses include atherosclerosis and arteriogenesis. Further evidence supporting this
hypothesis can be drawn from PAD patients with non-occluded vessels that still present
with impaired vasoactivity [26].
Using the mouse as a model for the simulation requires a significant portion of the
femoral-saphenous artery-vein pair must be removed, in order to generate sufficient
levels of hypoxia in the hindlimb and induce angiogenesis because of their extensive
collateral vascular networks. In this experiment, a modified resection surgery will remove
a section of the femoral artery. As a result, the hindlimb should become dependent on
reperfusion from deep collaterals in order to survive.
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Chapter 2. Project Design, Goals, and Hypothesis
In this study, arterial resection in the mouse hindlimb will be used to model the
chronic ischemia aspect of PAD. Using the mouse as a model for the simulation requires
a significant portion of the femoral-saphenous artery-vein pair to be removed in order to
generate sufficient levels of hypoxia in the hindlimb and induce angiogenesis because of
their extensive collateral vascular networks. In this experiment, a modified resection
surgery will remove a section of the femoral artery. As a result, the hindlimb should
become dependent on reperfusion from deep collaterals in order to survive.
Since hypoxia is a primary stimulator of angiogenesis, we expect VEGF levels to
be elevated following ischemia-induced hypoxia. Similarly, HIF1α is important in
sensing low oxygen conditions. Since HIF1α is increased with hypoxia via positive
feedback activation, it is expected that HIF1α mRNA be elevated after inducing the
ischemic conditions.

Specific Aim 1: To develop reliable molecular biology protocols that can be used
to isolate nucleic acids and measure the gene expression levels of specific genesof-interest. The accuracy of this approach will be determined by measuring the
expression of genes HIF1α and VEGF, which are known to increase following
ischemia. We expect expression levels to be highest at day 7 following surgery,
and decline slightly at day 14.

Specific Aim 2: To determine if the modified resection surgery will be viable in
evaluating angiogenesis. The purpose of this aim is to validate phenotype
observations with molecular analysis.

13

Chapter 3. Methods
ANIMAL HUSBANDRY
All procedures for this study were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) of California Polytechnic State University.
Male C57/Bl/6 mice, aged between 7-9 weeks, were housed in a temperature controlled
room within the University Vivarium with four mice per micro-isolator cage. Mice were
monitored on a daily basis, given water and rodent chow, and maintained a 12 hour light/
12 hour dark schedule. Mice were provided with nesting material, a mouse house, and a
plastic tube. Isolation gowns were worn while changing cages to maintain aseptic
conditions.

CHRONIC ISCHEMIA SURGERY
Mice were anesthetized in an induction chamber using 5% isoflurane and oxygen.
Once unconscious, the animal was removed from the chamber, weighed, and prepared for
the surgery. Surgical preparation included shaving the incision site and then removing
excess fur using depilatory cream. Finally, the mouse was placed onto a heated surgical
stage in a supine position. Body temperature was monitored and maintained throughout
the procedure at ~35⁰C via a rectal thermistor and heating pad.
The site of incision was wiped with Nolvasan to disinfect the area and a sterile
drape was placed over the animal with an opening only over the surgical region. A skin
incision was then made on the medial part of the hindlimb and elongated proximally until
the abdominal wall was visible. Sterile saline solution was applied to the site of incision
via a sterile cotton swab to help prevent the tissue from desiccating and becoming
damaged.
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Once the incision site was fully opened and prepared, the epigastric fat pad was
cauterized and removed. Next, the femoral artery was separated from the paired nerve
and vein, and sutures were tied on either side of the profunda bifurcation as seen in
figure 5. Following the ligation around the bifurcation, the segment of the vessel between
the two sutures was resected.

Profunda femoris artery
Profunda femoris vein

Saphenous artery & vein

Gracilis muscles & collaterals

Figure 5. Mouse hind limb used to model the ischemic conditions caused
by vascular occlusions. “X’s” on the femoral artery, on both the distal and
proximal sides of the profunda bifurcation, represent suture locations. The
dashed line represents the segment of femoral artery resected.
On the opposite hindlimb, an incision was made equivalent in size and location.
Again, sterile saline was used to prevent tissue desiccation. The fat pad and connective
tissue were blunt dissected as they were on the experimental leg. This sham surgery was
performed on the animal’s right leg to serve as a control for the potential impact of the
surgery on vascular remodeling.
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Incisions were closed using a 7.0 polypropylene suture and the mouse was given a
subcutaneous injection of buprenorphine (0.07 mg/kg). Animals were then placed back in
their appropriate cage and given 7 or 14 days to recover, depending on their assigned
time before their tissue was dissected.

TISSUE DISSECTION AND PRESERVATION
The gastrocnemius muscle was exposed by dissecting superficial musculature.
The gastrocnemius was then blunt dissected away from other muscle and separated away
from the tibia and fibula. The muscle was dissected from the calcaneal tendon to its
insertion at the condyles of the femur.
Immediately follow the dissection from the mouse, the tissue was placed in 1
volume (~1 mL) of RNAlater Stabilization solution (Invitrogen) and stored overnight at
4 C (Appendix A). After the overnight incubation the tissue was removed from solution
and place in a fresh microcentrifuge tube. Once in a new tube, the samples were
transferred to a -20 C freezer where they could be stored indefinitely.

TISSUE PREPARATION, RNA ISOLATION, QUANTIFICATION, AND QUALIT Y
ASSESSMENT
Tissue was homogenized using a Wheaton Glass Homogenizer (figure 6). Total
RNA was isolated using Qiagen fibrous tissue mini kit (Appendix B), which is ideal for
muscle tissues weighing less than 30 mg. -mercaptoethanol was added to lysis buffer to
aid in RNase denaturation. An on-column DNA digest was performed using Qiagen
DNase I kit. Water was used to wash the salts and release the nucleic acids from the
membrane. Following isolation, the RNA was quantified using UV spectrophotometry
(Thermo Scientific Nanodrop 2000) (figure 7). In order to quantify, the
spectrophotometer was zeroed with water and the absorbance was measured across the
16

spectrum from 200 to 300 nanometers (Appendix C). In order to check the integrity of the
RNA isolated, a 1% agarose gel containing ethidium bromide was run at 125V for about
45 minutes using 1X TAE running buffer. The gel was then imaged under UV light and
the ribosomal bands were analyzed. Upon analysis of the RNA, high quality samples
were carried on to the next part of the experiment.

Figure 6. Wheaton®
Glass Homogenizer
used to homogenize
tissue [27].

Figure 7. Thermo
scientific Nanodrop
2000 used to quantify
nucleic acid
concentration [28].

REVERSE TRANSCRIPTION, PCR, AND REAL-TIME PCR
RNA was converted into cDNA using the AffinityScript Multiple Temperature
Reverse Trancriptase kit from Agilent Technologies with oligo-dT primers annealed at
48 C. Using the concentration provided from the nanodrop spectrophotometer analysis,
2000 ng of total RNA was added to each reverse transcription reaction. HIF1α, VEGF,
and -actin primers were designed for real time PCR; table 1 shows the nucleotide
sequences for the oligo-nucleotide primers designed from gene database information and
messenger RNA sequences. -actin was used as the internal control gene to normalize the
amount of RNA added to each PCR reaction.
Primers were designed to bind to the messenger RNA transcripts of genes using
the sequences provided from the NCBI database (Appendix D). The primers bind to very
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specific sequences of DNA, or in this case cDNA and provide the three prime alcohol
group on the nucleic acid essential for polymerase to catalyze the phosphodiester bond
formed while replicating the nucleic acid template. BLAST was used to assure that the
primers were specific and unique in the Mus musculus genome.
Following the completion of cDNA synthesis, primers were optimized using
gradient PCR with annealing temperatures from 54-62 C using Qiagen HotStar Taq DNA
Polymerase in 25 L reaction volumes. Reactions were prepared according to Appendix
E and the cycle conditions were performed using manufacturer recommendations.
Qiagen QuantiFast SYBR Green (figure 8) PCR Kit was used for real time
detection using an Applied Biosystems

7500 Fast Real-time PCR System. The real time

protocol was 40 cycles of denaturing, annealing, and extending phases. An annealing
temperature of 58 C was used for all primer sets. After the final cycle, a dissociation
stage was used to ensure that there was no contamination within the sample. Samples
were analyzed in triplicate reactions and the CT values were averaged together. Also,
non-template controls were run with each primer set.
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Figure 8. Diagram of SYBR green detector functions
during the PCR to determine the amount of transcript
present. Fluorescence is detected by Applied
Biosystems thermocycler [29].

Table 1. Primers used during real time PCR gene expression analysis. Including sequences,
primer size, and expected amplicon size.
Primer

Sequence

Primer Size

Amplicon Size

HIF 1a forward

5’-agttacagaaacctaccatcactgc-3’

25

136

HIF 1a reverse

5’-tcttgaggtacttgggtagaagatg-3’

25

VEGF forward

5’-ctctctcttatttgacttgtgtgtgtg-3’

28

VEGF reverse

5’-aatatcttctcaggacaagctagtgac-3’

27

-actin forward

5’-ctgacagactacctcatgaagatcc-3’

25

-actin reverse

5’-gtctagagcaacatagcacagcttc-3’

25

133

114
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DATA ANALYSIS USING THE
METHOD
Using the
method [30], the data collected was measured as the fold change
in gene expression after normalization to the reference gene. A comparison was then
made between control and treatment groups. For the treatment group, evaluation of the
value indicates the fold change in gene expression relative to the untreated control
group. A one way T-test was used for statistical comparison between groups. A p-value
less that 0.05 was considered statistically significant.
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Chapter 4. Results
RNAlater® Stabilization solution provided an effective and reliable method of
preservation following dissection from the mice. Figure 9 shows total RNA isolated from
gastrocnemius muscles. Overall RNA quality was assessed by observing the ribosomal
RNA bands in the agarose gel image. The bands seen in samples (lanes 2-8 of figure 9)
are the 28s and 18s bands that make up eukaryotic ribosomes. The top band in each lane,
28s is roughly twice as bright as the 18s band, as expected in the absence of RNA
degradation. Therefore, it is assumed that messenger RNA was not significantly degraded
during the isolation process. As an additional check for RNA quality, there were no signs
of small segments of degraded RNA, which present as a “smear” towards the bottom of
the gel image. An example of this is shown in Appendix F. Similarly, there was no
evidence of genomic DNA contamination in the sample, which would have presented as a
large band towards the top of the gel image. The smears observed in figure 9 represent
messenger RNA.
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3

4

5

6

7

8

Figure 9. Gel electrophoresis visualization of total RNA isolated from gastrocnemius
samples. Total RNA was separated using a 1% non-denaturing agarose gel containing
ethidium bromide and photographed under ultraviolet light. The gel was run at 125V
for 45 minutes. The two bands in each sample represent the ribosomal RNA bands.
Lane 1 contains Promega 1kb standard ladder.
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Once quality RNA was reverse transcribed into cDNA, PCR primers were
optimized to ensure proper annealing temperatures for the real-time PCR. The highest
quality amplicon was generated when primers were annealed at 58°C, as observed in
figure 10. The high quality was assessed by looking for the brightest and sharpest band
of the amplicons. These characteristics combined represent consistent and accurate
binding of the primers, while not making the temperature too high to where the primers
are unable to bind. The same annealing temperature was used for all sets of primers
during the real-time PCR experiments following primer optimization.
°C: 54

55

56

57

58

59

60

61

Figure 10. Gel electrophoresis visualization of gradient PCR
amplicons. The bands were separated using a 2% nondenaturing agarose gel containing ethidium bromide and
photographed under ultraviolet light. Gel was run at 125V for
45 minutes. PCR gradient was used to determine the optimal
annealing temperature for primers. In this case, VEGF
amplicons were analyzed and 58 C happened to generate the
highest quality band.
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Using one set of primers per reaction, all samples were analyzed in one reaction,
in a single 96-well tray. The results of one reaction are displayed in figure 11. The image
shows little observable fluorescence during the early stages. However, after about 20 or
so cycles, exponential amplification is observed, as expected. The fluorescence begins to
plateau towards the latter cycles as the primers become limiting reactants.

Figure 11. Real time PCR amplification plot of gastrocnemius muscle samples using
HIF1a primers. Primers were annealed at 58 C. An extension time of 30 seconds was
used.
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In order to extract the CT value from the reaction data, the graph was converted
into change per reaction vs cycle number, as shown in figure 12. The threshold value was
chosen at a value where the amplification curve was steepest in all samples. A
dissociation-curve analysis was also performed to determine the melting temperature of a
single target nucleic acid sequence. Therefore, if there were any contamination within the
sample, an errant curve would be generated.

Figure 12. Real time PCR amplification plot of gastrocnemius muscle samples using
HIF1a primers. The horizontal line represents the threshold used to analyze the samples.

The CT values for HIF-1α and VEGF can be found in tables 2-5. From these
values, the bar graphs were generated for visual comparison of the data (figures 13 and
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14). The analysis reveals no significant changes in HIF1α expression following the
surgery. Conversely, there was a significant increase in VEGF expression at both 7 and
14 days. VEGF expression levels dropped significantly between the day 7 and day 14
time points in experimental tissue as well.
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Table 2. Replicate day 7 CT data comparison of HIF1α and β-actin reference amplified in separate wells.
Data generated using real-time PCR with SYBR green detector.
Tissue

Sham

Average
Day 7

Average

HIF1α

β-actin

20.99
21.40
21.48
21.29 ± 0.15
21.18
20.23
18.62
20.01 ± 0.75

15.88
16.14
16.32
16.11 ± 0.13
15.89
15.18
13.55
14.88 ± 0.69

ΔCT (Avg. HIF1α
CT – Avg. β-actin
CT)

ΔΔCT (Avg. ΔCT,Sham
– Avg. ΔCT)

Normalized HIF1α
amount relative to Sham

5.18 ± 0.04

0.00 ± 0.04

1.00(0.97-1.03)

5.13 ± 0.07

0.05 ± 0.07

0.97(0.92-1.01)

Table 3. Replicate day 14 CT data comparison of HIF1α and β-actin reference amplified in separate
wells. Data generated using real-time PCR with SYBR green detector.
Tissue

Sham

Average
Day 14

β-actin

21.40
22.18
21.63
21.05
21.57 ± 0.24
23.47
21.09
21.02
20.89
21.62 ± 0.62

15.94
16.57
16.41
15.73
16.16 ± 0.20
17.06
15.30
15.69
15.85
15.97 ± 0.38

Fold change in Hif1a gene expresssion

Average

HIF1α

ΔCT (Avg. HIF1α
CT – Avg. β-actin
CT)

ΔΔCT (Avg. ΔCT,Sham
– Avg. ΔCT)

Normalized HIF1α
amount relative to Sham

5.41 ± 0.09

0.00 ± 0.09

1.00(0.94-1.06)

5.65 ± 0.30

-0.24 ± 0.30

1.18(0.96-1.45)

1.5

1

0.5

0
-1

4

9

14

Time (days)

Figure 13. Delta CT analysis of HIF1α compared against β-actin in gastrocnemius muscle. Results
measured at days 7 and 14 in both experimental and sham tissue. The error bars represent the standard
error of the mean.
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Table 4. Replicate day 7 CT data comparison of VEGF and β-actin reference amplified in separate
wells. Data generated using real-time PCR with SYBR green detector.
Tissue

Sham

Average
Day 7

Average

VEGF

β-actin

17.64
17.74
17.19
17.52 ± 0.17
18.29
18.04
19.58
18.64 ± 0.48

15.88
16.14
16.32
16.11 ± 0.13
15.89
15.18
13.55
14.88 ± 0.69

ΔCT (Avg. VEGF CT
– Avg. β-actin CT)

ΔΔCT (Avg. ΔCT,Sham
–Avg. ΔCT )

Normalized VEGF
amount relative to Sham

1.41 ± 0.27

0.00 ± 0.27

1.00(0.83-1.21)

3.76 ± 1.14

-2.35 ± 1.14

5.10(2.31-11.24)

Table 5. Replicate day 14 CT data comparison of VEGF and β-actin reference amplified in separate
wells. Data generated using real-time PCR with SYBR green detector.
Tissue

Sham

Average
Day 14

Average

VEGF

β-actin

17.47
18.49
17.48
16.80
17.56 ± 0.35
18.69
17.53
18.27
17.12
17.90 ± 0.35

15.94
16.57
16.41
15.73
16.16 ± 0.20
17.06
15.30
15.69
15.85
15.97 ± 0.38

ΔCT (Avg. VEGF
CT – Avg. β-actin
CT)

ΔΔCT (Avg. ΔCT,Sham
– Avg. ΔCT)

Normalized VEGF
amount relative to Sham

1.40 ± 0.21

0.00 ± 0.21

1.00(0.86-1.16)

1.93 ± 0.29

-0.53 ± 0.29

1.44(1.18-1.77)

Fold change in Vegf gene expresssion

12

**

10
8
6
4

*

2
0
-1

4

9

14

Time (days)

Figure 14. Delta CT analysis of VEGF compared against β-actin in gastrocnemius muscle. Results
measured at days 7 and 14 in both experimental and sham tissue. The error bars represent the standard
error of the mean.
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Chapter 5. Discussion
PAD is a vascular condition characterized by the narrowing of blood vessels
caused by the buildup of atherosclerotic plaques and the reduced reactivity of
downstream vessels. Together, these factors result in ischemia and cause damage to the
effected tissue. As an adaptive mechanism, blood is redistributed amongst collateral
vessels, which in turn results in increased shear stress within those vessels and causes
them to outwardly remodel. However, outward remodeling itself may impair vasodilation
and lead to ischemic limb pain in patients. Impaired vasodilation might be caused by
changes in cell type during the angiogenesis process, specifically the transition of smooth
muscle cells from contractile to synthetic. It may also be caused from the relocation of
cells during mechanoadaptation. A third possibility for the observed impairment in
vasodilation could be a decrease in endothelial-derived nitric oxide as a result of
inflammation brought on by the increased shear stress. Inducing vascular remodeling in
patients with vascular occlusions is a promising new route in the treatment of PAD.
However, to create an effective therapy, the impact of vascular growth on vasoactivity
must first be better understood.
The first objective of this project was to develop reliable molecular biology
protocols that could be used to evaluate vascular remodeling and vasoactivity. As
evidenced by figures 9, 10, 11 & 12, the protocols developed successfully yielded
consistent, high-quality nucleic acid isolations and precise real-time PCR reactions.
Several different aspects of molecular biology were addressed and developed during this
project, and a great deal of optimization was required for the PCR protocol.
Primers for PCR were selected if they met several prerequisites. First, the
amplicon generated had to be short, less than 150 base pairs. This is a requirement of
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primers that will later be used during real-time PCR because it allows for polymerase to
bind, amplify, and unbind quickly. Second, primers had to be slightly longer than lose
used during regular PCR to ensure nonspecific binding did not occur. In this case, each
primer was at least 25 base pairs in length. Third, the melting temperatures between each
primer of the pair had to be highly similar to each other to allow for efficient annealing.
Finally, the final base pair at the three prime end had to be either a guanine or cytosine.
The second objective of this project was to determine if the modified resection
surgery was a viable method in evaluating angiogenesis. The results for this are shown in
figures 13 & 14. The increase in Vegf expression in the day 7 measurement following
surgery indicates that the surgery sufficiently created a hypoxic environment in the
downstream tissue. Vegf was most elevated when measured 7 days after the surgery. The
decrease in Vegf expression from day 7 to day 14, suggests that the signals for
vasculogenesis and angiogenesis were present and that these phenomenon may have been
acting to remodel the vascular network and improve tissue oxygen extraction. The
significant decrease in Vegf transcript levels between days 7 and 14 following the
surgery, suggests that vascular remodeling caused a decrease in tissue hypoxia. The
value, however, was still higher than the sham, which implies that after 14 days the tissue
remains slightly hypoxic and continued vascular remodeling was still necessary.
Surprisingly, there were no significant changes in Hif1α expression between the
sham and experimental tissues at either 7 or 14 days (figure 13). These results suggest
that the modified ischemic model induces a less severe hypoxia than the traditional
ischemia model that involves resection of the entire femoral-saphenous artery-vein pair.
From the Vegf increase it is apparent that the tissue became hypoxic, however, the Hif1α
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results suggest that the hypoxia was not enough to generate the positive feedback of
Hif1α necessary for the increase in its transcription [31]. These assumptions can be easily
verified using protein quantification, such as a western blot analysis. Results from a
western blot would be able to detect the amount of Hif1α present and help confirm that
more active amounts of protein are present even though there was no significant increase
in transcript level.
The results from this project do not provide conclusions regarding the relationship
between vascular remodeling and vasoactivity, but rather provides the necessary
techniques required to investigate this topic. For example, measurement of Embyronic
smooth muscle myosin (SMemb) would provide an independent measure of
arteriogenesis. This would provide valuable information on the remodeling process and
the impaired vasodilation observed during arteriogenesis that is thought to be caused by
the phenotype changes the vascular smooth muscle cells.
Another application of the protocols and procedures developed in this project is
the analysis of gene delivery techniques. Plasmids are being developed that would allow
genes, such as Vegf, to be delivered directly into the tissues of experimental animals,
which would allow for both gain- and loss-of-function studies at the genetic level. Using
the real-time protocols developed for this project, the efficiency of transgene expression
could be easily measured.
Overall, the protocols developed in during this project allowed for an accurate and
concise analysis of the genes investigated. The modified resection surgery was sufficient
in creating a hypoxic environment downstream to the point where the genes involved in
vascular remodeling were significantly up-regulated. Upcoming studies using this model
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should incorporate protein analysis to gain a more complete picture of the environment at
the molecular level. Better understanding the interactions between vasodilation and
vascular remodeling can guide the development of novel treatments for patients afflicted
with PAD.
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APPENDIX A
TISSUE DISECTION PROTOCOL

35

APPENDIX B
RNA ISOLATION PROTOCOL
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APPENDIX C
RNA ANALYSIS PROTOCOL
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APPENDIX D
ADDITIONAL INFORMATION REGARDING PRIMER DESIGN
The final base pair at the three prime end had to be either a guanine or cytosine.
These nucleic acids, when bonded with each other in a double stranded manner, are held
together by three hydrogen bonds, rather than the two that hold together adenine and
thymine base pairs. This extra hydrogen bond helps ensure that the three prime end of the
primer is firmly attached to its template before amplification begins.

APPENDIX E
MODIFIED PCR AMPLIFICATION PROTOCOL
The concentration of reagents was modified from manufacturer protocol to a more
efficient reaction that was found to produce better results.

Date__________
MASTER MIX REAGENTS
ADDED TO MM
PCR Buffer
Q Solution
Hot Star Taq Pols
MgCl2
dNTPs
Di H2O

ADDED AFTER MM ALIQUOTED
Primer
Amount sample

PCR Master Mix Protocol

Initials__________

INITIAL CONC

FINAL CONC

1 RXN (µL)

10X
5X
5U / µL
25 mM
10 mM

1X
1X
2.5U / rxn
2.5 mM
0.20 mM

2.5
5
0.5
2.5
0.5
9

VOLUME / ALIQUOT (µL)

20

1 µM
250 ng
TOTAL RXN VOL (µL)

2.5
2.5
25

10 µM
100 ng/µL

Notes:
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APPENDIX F
The image below is an example of an isolation of heavily degraded RNA. The
bright band towards the bottom of the gel image in lane 4 is an example of heavily
degraded RNA. RNA this heavily degraded cannot be used for later experiments such as
real-time PCR for gene expression analysis because the results will be inaccurate.

1

2

3

4

5

6
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APPENDIX G
REAL-TIME PCR DATA FOR HIF1Α
The fluorescence begins to plateau towards the latter cycles as the primers
become limiting reactants. By that point in the reaction, the concentration of primers is
not high enough in solution to maintain the trend and amplification ceased. Also, with
each primer set, a non-template control sample was used to confirm that SYBR green
detection was in fact from the amplification of transcripts.
Document Name: AT primer 7 C11-D12
Plate Type: Standard Curve
User: CAFES USER
Document Information
Operator: CAFES USER
Run Date: Monday
March 19
2012 21:24:00
Last Modified: Tuesday
March 20
2012 11:37:31
Instrument Type: Applied Biosystems 7500 Fast Real-Time PCR System
Exporting Mode: Based on Selected Wells and Report Setting
Comments:
SDS v1.4
Thermal Cycler Profile
Stage
Repetitions
1
2

3 (Dissociation)

Temperature
1 95.0 ! C
40 94.0 ! C
58.0 ! C
72.0 ! C
1 95.0 ! C
60.0 ! C
95.0 ! C
60.0 ! C

Time
15:00
0:15
0:30
0:30
0:15
1:00
0:15
0:15

Ramp Rate
Auto
Auto
Auto
Auto
Auto
Auto
Auto
Auto

Auto Increment

Ct

StdDev Ct
0.136-999.9
0.136-999.9
0.136-999.9
0.106-999.9
0.106-999.9
0.106-999.9
0.102-999.9
0.102-999.9
0.102-999.9
0.0876-999.9
0.0876-999.9
0.0876-999.9
0.111-999.9
0.111-999.9
0.111-999.9
0.0914-999.9
0.0914-999.9
0.0914-999.9
0.117-999.9
0.117-999.9

Fast 7500 Mode
Data Collection : Stage 2 Step 3
PCR Volume: 20 " L
Well
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
B1
B2
B3
B4
B5
B6
B7
B8

Sample Name
C11 Primer 7
C11 Primer 7
C11 Primer 7
C12 Primer 7
C12 Primer 7
C12 Primer 7
D1 Primer 7
D1 Primer 7
D1 Primer 7
D2 Primer 7
D2 Primer 7
D2 Primer 7
D3 Primer 7
D3 Primer 7
D3 Primer 7
D4 Primer 7
D4 Primer 7
D4 Primer 7
D5 Primer 7
D5 Primer 7

Detector
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR

Task
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown

21.2963
21.3609
21.5574
23.3481
23.5331
23.5301
22.2525
22.2278
22.0649
21.0123
21.1868
21.0855
21.5033
21.7075
21.6828
20.9387
21.0102
21.1202
21.1821
20.9872

Tm
77.2
77.2
77.2
77.2
77.2
77.5
77.5
77.2
77.2
77.2
77.2
77.2
77.2
77.5
77.5
77.5
77.5
77.5
77.5
77.5

40

B9
B10
B11
B12
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
D1
D2
D3
D4
D5
D6
D7

D5 Primer 7
D6 Primer 7
D6 Primer 7
D6 Primer 7
D7 Primer 7
D7 Primer 7
D7 Primer 7
D8 Primer 7
D8 Primer 7
D8 Primer 7
D9 Primer 7
D9 Primer 7
D9 Primer 7
D10 Primer 7
D10 Primer 7
D10 Primer 7
D11 Primer 7
D11 Primer 7
D11 Primer 7
D12 Primer 7
D12 Primer 7
D12 Primer 7
NTC Primer 7

SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR
SYBR

Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
NTC

20.9741
20.8359
21.0668
20.7528
20.7743
20.991
21.2071
21.1458
21.1805
21.2003
21.3617
21.4545
21.3927
20.2274
20.3836
20.0916
21.5241
21.3261
21.5831
18.7977
18.7229
18.3267
38.0194

0.117-999.9
0.163-999.9
0.163-999.9
0.163-999.9
0.216-999.9
0.216-999.9
0.216-999.9
0.0276-999.9
0.0276-999.9
0.0276-999.9
0.0472-999.9
0.0472-999.9
0.0472-999.9
0.146-999.9
0.146-999.9
0.146-999.9
0.135-999.9
0.135-999.9
0.135-999.9
0.253-999.9
0.253-999.9
0.253-999.9
-999.9

77.5
77.5
77.5
77.5
77.5
77.9
77.9
77.9
77.9
77.9
77.9
77.9
77.9
77.9
77.9
77.5
77.5
77.9
77.9
78.2
78.2
78.2
77.5
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APPENDIX H
REAL-TIME PCR DATA FOR VEGF
Document Name: Primer 10 C11-D12
Plate Type: Standard Curve
User: CAFES USER
Document Information
Operator: CAFES USER
Run Date: Tuesday
March 20
2012 13:03:50
Last Modified:
Instrument Type: Applied Biosystems 7500 Fast Real-Time PCR System
Exporting Mode: Based on Selected Wells and Report Setting
Comments:
SDS v1.4
Thermal Cycler Profile
Stage
Repetitions
Temperature
1
1 95.0 ! C
2
40 94.0 ! C
58.0 ! C
72.0 ! C
3 (Dissociation)
1 95.0 ! C
60.0 ! C
95.0 ! C
60.0 ! C
Fast 7500 Mode
Data Collection : Stage 2 Step 3
PCR Volume: 20 " L
Well
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
B1
B2
B3
B4
B5
B6
B7
B8

Sample Name Detector
C11 Primer 10 SYBR
C11 Primer 10 SYBR
C11 Primer 10 SYBR
C12 Primer 10 SYBR
C12 Primer 10 SYBR
C12 Primer 10 SYBR
D1 Primer 10 SYBR
D1 Primer 10 SYBR
D1 Primer 10 SYBR
D2 Primer 10 SYBR
D2 Primer 10 SYBR
D2 Primer 10 SYBR
D3 Primer 10 SYBR
D3 Primer 10 SYBR
D3 Primer 10 SYBR
D4 Primer 10 SYBR
D4 Primer 10 SYBR
D4 Primer 10 SYBR
D5 Primer 10 SYBR
D5 Primer 10 SYBR

Time
15:00
0:15
0:30
0:30
0:15
1:00
0:15
0:15

Ramp Rate
Auto
Auto
Auto
Auto
Auto
Auto
Auto
Auto

Task
Ct
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown

17.4152
17.4305
17.569
18.6176
18.7087
18.7297
18.6099
18.5293
18.3223
17.8149
17.7977
16.966
17.4624
17.5023
17.4675
18.2137
18.2735
18.3265
16.9941
16.7111

Auto Increment

StdDev Ct
Tm
0.0847-999.9
78
0.0847-999.9
78
0.0847-999.9
78
0.0596-999.9
78
0.0596-999.9 78.4
0.0596-999.9 78.4
0.148-999.9
78.4
0.148-999.9
78.4
0.148-999.9
78
0.485-999.9
78
0.485-999.9
78
0.485-999.9
78
0.0217-999.9
78
0.0217-999.9 78.4
0.0217-999.9 78.4
0.0564-999.9 78.4
0.0564-999.9 78.4
0.0564-999.9 78.4
0.171-999.9
78.4
0.171-999.9
78.4
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B9
B10
B11
B12
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
D1
D2
D3
D4
D5
D6
D7

D5 Primer 10 SYBR
D6 Primer 10 SYBR
D6 Primer 10 SYBR
D6 Primer 10 SYBR
D7 Primer 10 SYBR
D7 Primer 10 SYBR
D7 Primer 10 SYBR
D8 Primer 10 SYBR
D8 Primer 10 SYBR
D8 Primer 10 SYBR
D9 Primer 10 SYBR
D9 Primer 10 SYBR
D9 Primer 10 SYBR
D10 Primer 10SYBR
D10 Primer 10SYBR
D10 Primer 10SYBR
D11 Primer 10SYBR
D11 Primer 10SYBR
D11 Primer 10SYBR
D12 Primer 10SYBR
D12 Primer 10SYBR
D12 Primer 10SYBR
Primer 10 NTCSYBR

Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
NTC

16.6862
17.0526
17.2266
17.0948
17.5036
17.5661
17.8482
18.1287
18.4606
18.2781
17.7045
17.7911
17.7376
18.0978
18.253
17.7626
17.2861
17.0507
17.2288
19.5339
19.6372
19.5838
37.7438

0.171-999.9
0.0908-999.9
0.0908-999.9
0.0908-999.9
0.184-999.9
0.184-999.9
0.184-999.9
0.166-999.9
0.166-999.9
0.166-999.9
0.0437-999.9
0.0437-999.9
0.0437-999.9
0.251-999.9
0.251-999.9
0.251-999.9
0.123-999.9
0.123-999.9
0.123-999.9
0.0517-999.9
0.0517-999.9
0.0517-999.9
-999.9

78.4
78.4
78.4
78.4
78.4
78.7
78.7
78.7
78.7
78.7
78.7
78.7
78.7
78.7
78.7
78.4
78.7
78.7
79.1
79.1
78.7
78.7
78
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APPENDIX I
REAL-TIME PCR DATA FOR β-ACTIN
Document Name: AT primer 13 C11-D12
Plate Type: Standard Curve
User: CAFES USER
Document Information
Operator: CAFES USER
Run Date: Wednesday
March 21
2012 11:25:52
Last Modified: Wednesday
March 21
2012 13:17:13
Instrument Type: Applied Biosystems 7500 Fast Real-Time PCR System
Exporting Mode: Based on Selected Wells and Report Setting
Comments:
SDS v1.4
Thermal Cycler Profile
Stage
Repetitions
Temperature
1
1 95.0 ! C
2
40 94.0 ! C
58.0 ! C
72.0 ! C
3 (Dissociation)
1 95.0 ! C
60.0 ! C
95.0 ! C
60.0 ! C
Fast 7500 Mode
Data Collection : Stage 2 Step 3
PCR Volume: 20 " L
Well
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
B1
B2
B3
B4
B5
B6
B7
B8

Sample Name Detector
C11 Primer 13 SYBR
C11 Primer 13 SYBR
C11 Primer 13 SYBR
C12 Primer 13 SYBR
C12 Primer 13 SYBR
C12 Primer 13 SYBR
D1 Primer 13 SYBR
D1 Primer 13 SYBR
D1 Primer 13 SYBR
D2 Primer 13 SYBR
D2 Primer 13 SYBR
D2 Primer 13 SYBR
D3 Primer 13 SYBR
D3 Primer 13 SYBR
D3 Primer 13 SYBR
D4 Primer 13 SYBR
D4 Primer 13 SYBR
D4 Primer 13 SYBR
D5 Primer 13 SYBR
D5 Primer 13 SYBR

Time
15:00
0:15
0:30
0:30
0:15
1:00
0:15
0:15

Ramp Rate
Auto
Auto
Auto
Auto
Auto
Auto
Auto
Auto

Task
Ct
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown

15.8949
15.8978
16.0277
16.9606
17.1263
17.0818
16.7705
16.5714
16.3706
15.3161
15.4255
15.1555
16.3013
16.608
16.3346
15.5399
15.7172
15.8021
15.9946
15.6791

Auto Increment

StdDev Ct
Tm
0.0758-999.9 80.4
0.0758-999.9 80.4
0.0758-999.9 80.4
0.0858-999.9 80.4
0.0858-999.9 80.7
0.0858-999.9 80.7
0.2-999.9
80.7
0.2-999.9
80.7
0.2-999.9
80.4
0.136-999.9
80.4
0.136-999.9
80.4
0.136-999.9
80.4
0.168-999.9
80.4
0.168-999.9
80.4
0.168-999.9
80.7
0.134-999.9
80.7
0.134-999.9
80.7
0.134-999.9
80.7
0.248-999.9
80.7
0.248-999.9
80.7
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B9
B10
B11
B12
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
D1
D2
D3
D4
D5
D6
D7

D5 Primer 13 SYBR
D6 Primer 13 SYBR
D6 Primer 13 SYBR
D6 Primer 13 SYBR
D7 Primer 13 SYBR
D7 Primer 13 SYBR
D7 Primer 13 SYBR
D8 Primer 13 SYBR
D8 Primer 13 SYBR
D8 Primer 13 SYBR
D9 Primer 13 SYBR
D9 Primer 13 SYBR
D9 Primer 13 SYBR
D10 Primer 13SYBR
D10 Primer 13SYBR
D10 Primer 13SYBR
D11 Primer 13SYBR
D11 Primer 13SYBR
D11 Primer 13SYBR
D12 Primer 13SYBR
D12 Primer 13SYBR
D12 Primer 13SYBR
Primer 13 NTCSYBR

Unknown
15.5064
Unknown
15.8725
Unknown
15.8529
Unknown
15.8269
Unknown
15.6862
Unknown
15.8885
Unknown
16.0529
Unknown
15.7228
Unknown
15.9854
Unknown
15.9761
Unknown
16.162
Unknown
16.2303
Unknown
16.0277
Unknown
15.2259
Unknown
15.2715
Unknown
15.0399
Unknown
16.4124
Unknown
16.1816
Unknown
16.3556
Unknown
13.4667
Unknown
13.5432
Unknown
13.6461
NTC
Undetermined

0.248-999.9
0.0229-999.9
0.0229-999.9
0.0229-999.9
0.184-999.9
0.184-999.9
0.184-999.9
0.149-999.9
0.149-999.9
0.149-999.9
0.103-999.9
0.103-999.9
0.103-999.9
0.123-999.9
0.123-999.9
0.123-999.9
0.12-999.9
0.12-999.9
0.12-999.9
0.09-999.9
0.09-999.9
0.09-999.9

80.4
80.7
80.7
80.4
80.4
80.7
80.7
81.1
81.1
81.1
80.7
80.7
80.7
81.1
80.7
80.7
80.7
81.1
81.1
81.4
81.4
81.1
65.7
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